]>
IRCT2016111016123N11 IRCT 2017-02-20 Vice Chancellor for Research and Technology, Ahvaz Jundishapur University of Medical Sciences Effects of Melatonin on Metabolic Syndrome disease Evaluation of the effects of Melatonin Supplementation on metabolic Syndrome components and plasma Leptin and Adiponectin levels in patients with metabolic Syndrome 2017-01-29 anticipated 80 Complete https://irct.ir/trial/15189 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. N/A metabolic syndrome. Intervention 1: Melatonin, Tab 5 mg, once a dayT 3 months. Intervention 2: Placebo, 5 mg, 3 months.
public Sima Jafarirad
Ahvaz Jundishapur University of Medical Sciences, Golestan, Ahvaz, Iran
Ahvaz Iran (Islamic Republic of) +98 61 3336 7560 sjafarirad@gmail.com Ahvaz Jundishapur University of Medical Sciences scientific Sima Jafarirad
Ahvaz Jundishapur University of Medical Sciences, Golestan, Ahvaz, Iran
Ahvaz Iran (Islamic Republic of) +98 61 3336 7560 sjafarirad@gmail.com Ahvaz Jundishapur University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: Age 18 years and older; having at least two of the five metabolic syndrome criteria including waist circumference in men greater than or equal to 102 cm and in women greater than or equal to 88 cm; triglycerides levels (TG) greater than or equal to 150 mg/dL; low-density lipoprotein cholesterol levels (HDL-c) less than or equal to 40 mg/dL in men and less than or equal to 50 mg/dL in women; blood pressure greater than or equal to 130 mmHg or under treatment of Hypertension; fasting blood sugar greater than or equal to 100 mg/dL. b -exclusion criteria: history of alcohol consumption; chronic and acute liver disorders (hepatitis B, C, ...); biliary diseases; autoimmune diseases; cancer; cardiovascular diseases; pulmonary diseases; kidney diseases; pregnancy; breast-feeding; use of contraceptives; hepatotoxic drugs consumption; use of Mineral- multivitamin supplements; weight loss surgery in the recent year; weight loss program in 3 month ago; history of hypothyroidism; Cushing's syndrome. 18 years 60 years Both E90 Nutritional and metabolic disorders in diseases classified elsewhere Other Placebo Melatonin, Tab 5 mg, once a dayT 3 months Placebo, 5 mg, 3 months Triglyceride. Timepoint: before intervention and after 3 months. Method of measurement: serum level. Total cholesterol. Timepoint: before intervention and after 3 months. Method of measurement: serum level. High density lipoprotein (HDL). Timepoint: before intervention and after 3 months. Method of measurement: serum level. Low density lipoprotein (LDL). Timepoint: before intervention and after 3 months. Method of measurement: serum level. Leptin. Timepoint: before intervention and after 3 months. Method of measurement: serum level. Adiponectin. Timepoint: before intervention and after 3 months. Method of measurement: serum level. Fasting blood sugar. Timepoint: before intervention and after 3 months. Method of measurement: serum level. Blood pressure. Timepoint: before intervention and after 3 months. Method of measurement: Blood Pressure Monitor. Waist circumference. Timepoint: before intervention and after 3 months. Method of measurement: Tape measure. Sleep quality. Timepoint: before intervention and after 3 months. Method of measurement: questionnaire. Vice Chancellor for Research and Technology, Ahvaz Jundishapur University of Medical Sciences Approved 2017-01-21 ٍEthics Committee of Ahvaz Jundishapur University of Medical Sciences Ahvaz Jundishapur University of Medical Sciences, Golestan, Ahvaz, Iran Ahvaz Iran (Islamic Republic of)